Additional Relevant Details Human Study • Among premenopausal women with HSDD with or without FSAD, subcutaneous (SC) administration of BMT 1.25 mg or 1.75 mg significantly increased the number of sexually satisfying events (SSEs) versus placebo when taken 45 minutes before sexual activity. —Mean change (standard error) in number of SSEs from baseline to study end was +0.7 (2.4) events/ month for BMT 1.25/1.75 mg pooled, compared with +0.2 (2.3) for placebo BMT was associated with decreases in both total score and the desire, arousal, and orgasm items of the Female Sexual Distress Scale–Desire-ArousalOrgasm (FSDS-DAO) measure. —Mean change in FSDS-DAO was –11.1 (12.0) with BMT versus –6.8 (13.6) with placebo; P=0.0014. Decreasing value represents less distress